Obesity and pharmacology experts are warning about hidden safety risks and efficacy issues for many types of medications in people with obesity.

Products must note that they can increase blood pressure, but boxed warnings about adverse cardiovascular events can be ...

The U.S. Food and Drug Administration said on Friday it issued new labeling changes for testosterone products based on results from clinical and post-market studies testing the products for blood ...

The FDA has developed draft guidance addressing confusion and legal action over the naming and labeling of plant-based alternatives to eggs, ...

Regulatory and reimbursement pathways should consider indirect benefits in addition to direct health benefits when evaluating ...

Experts caution that the terrorist designation of cartels may expose unsuspecting business owners to legal risks for unknowingly providing goods or services.

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that the U.S. Food and ...

The TRAVERSE trial, a large-scale clinical study with over 5,000 patients, published in 2023, concluded that TRT does not increase the risk of adverse cardiovascular outcomes in men with hypogonadism.

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment ...